WEBULL
News
MIRA
1.160
-1.69%
-0.020
Weekly Report: what happened at MIRA last week (0202-0206)?
Weekly Report · 5d ago
Mira Pharmaceuticals stellt Pipeline für neuartige orale Therapien bei neurologischen und psychiatrischen Erkrankungen vor
Reuters · 02/06 16:27
Mira Pharmaceuticals Unveils Pipeline Focused on Oral Therapies for Neurologic and Metabolic Disorders
Reuters · 02/06 16:27
Psychedelic: Analyst initiates Definium, Helus with Buy ratings
TipRanks · 02/05 15:40
Mira Pharmaceuticals initiates final cohort of Ketamir-2 Phase 1 study
TipRanks · 02/03 12:45
MIRA Pharmaceuticals Initiated Dosing In Final Cohort of Its Phase 1 Multiple Ascending Dose Trial Of Ketamir-2; The Company Expects to Complete the Phase 1 Clinical Program by the End of Q1 of 2026
Benzinga · 02/03 12:33
Mira Pharmaceuticals startet finale Phase-1-Studie mit Ketamir-2 gegen Chemotherapie-bedingte Neuropathie
Reuters · 02/03 12:30
Mira Pharmaceuticals Begins Final Phase 1 Trial Cohort for Oral Ketamir-2 in Neuropathic Pain
Reuters · 02/03 12:30
MIRA Pharmaceuticals Advances Ketamir-2 Phase 1 to Final Cohort
TipRanks · 02/02 21:42
Mira Pharmaceuticals Initiates Dosing Final Group Of Its Phase 1 Multiple Ascending Dose Clinical Study Of Ketamir-2
Benzinga · 02/02 21:04
Mira Pharmaceuticals Begins Final Dosing in Phase 1 Trial of Ketamir-2
Reuters · 02/02 21:02
Mira Pharmaceuticals startet letzte Phase-1-Kohorte für Ketamir-2 und plant Phase-2a-Studie
Reuters · 02/02 21:02
Weekly Report: what happened at MIRA last week (0126-0130)?
Weekly Report · 02/02 09:37
Weekly Report: what happened at MIRA last week (0119-0123)?
Weekly Report · 01/26 09:37
Weekly Report: what happened at MIRA last week (0112-0116)?
Weekly Report · 01/19 09:40
Weekly Report: what happened at MIRA last week (0105-0109)?
Weekly Report · 01/12 09:39
Weekly Report: what happened at MIRA last week (1229-0102)?
Weekly Report · 01/05 09:37
Weekly Report: what happened at MIRA last week (1222-1226)?
Weekly Report · 12/29/2025 09:36
Mira Pharmaceuticals Awards CEO Erez Aminov New Incentive Compensation Package
Reuters · 12/22/2025 11:03
Weekly Report: what happened at MIRA last week (1215-1219)?
Weekly Report · 12/22/2025 09:36
More
Webull provides a variety of real-time MIRA stock news. You can receive the latest news about Mira Pharma through multiple platforms. This information may help you make smarter investment decisions.
About MIRA
MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.